Sidoti Predicts Kamada’s Q1 Earnings (NASDAQ:KMDA)

Kamada Ltd. (NASDAQ:KMDA) – Analysts at Sidoti issued their Q1 2028 EPS estimates for Kamada in a research note issued to investors on Tuesday, August 18th. Sidoti analyst J. Sidoti expects that the biotechnology company will post earnings of $0.13 per share for the quarter. The consensus estimate for Kamada’s current full-year earnings is $0.49 per share. Sidoti also issued estimates for Kamada’s Q2 2028 earnings at $0.15 EPS.

Kamada (NASDAQ:KMDA) last released its quarterly earnings results on Wednesday, August 12th. The biotechnology company reported $0.16 earnings per share for the quarter, beating analysts’ consensus estimates of $0.11 by $0.05. Kamada had a net margin of 11.60% and a return on equity of 8.37%. The business had revenue of $54.92 million for the quarter, compared to the consensus estimate of $50.84 million.

A number of other research analysts also recently weighed in on the company. William Blair set a $15.00 price objective on Kamada in a research note on Tuesday, July 21st. Weiss Ratings lowered shares of Kamada from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday, June 25th. Benchmark restated a “buy” rating on shares of Kamada in a report on Tuesday, July 21st. Finally, Wall Street Zen upgraded Kamada from a “hold” rating to a “strong-buy” rating in a research note on Saturday. Three research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $13.00.

Kamada Price Performance

NASDAQ KMDA opened at $7.89 on Wednesday. Kamada has a fifty-two week low of $6.50 and a fifty-two week high of $9.35. The stock’s 50-day moving average is $7.25 and its two-hundred day moving average is $7.94. The firm has a market cap of $453.71 million, a P/E ratio of 20.76, a price-to-earnings-growth ratio of 0.67 and a beta of 0.86.

Kamada Cuts Dividend

The business also recently declared an annual dividend, which will be paid on Thursday, September 17th. Shareholders of record on Thursday, August 27th will be given a $0.17 dividend. This represents a yield of 219.0%. The ex-dividend date is Thursday, August 27th. Kamada’s dividend payout ratio (DPR) is currently 47.37%.

Institutional Investors Weigh In On Kamada

Institutional investors have recently added to or reduced their stakes in the company. Cubist Systematic Strategies LLC acquired a new position in Kamada in the 1st quarter valued at approximately $206,000. NewEdge Advisors LLC lifted its position in Kamada by 119.9% in the first quarter. NewEdge Advisors LLC now owns 51,661 shares of the biotechnology company’s stock worth $341,000 after purchasing an additional 28,165 shares during the period. Goldman Sachs Group Inc. acquired a new stake in Kamada during the first quarter worth $497,000. Jane Street Group LLC acquired a new position in shares of Kamada in the 1st quarter valued at $582,000. Finally, Arrowstreet Capital Limited Partnership acquired a new stake in shares of Kamada during the 2nd quarter valued at about $472,000. 20.38% of the stock is owned by institutional investors and hedge funds.

Kamada Company Profile

Kamada Ltd. is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma‐derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.

Among Kamada’s marketed products is Glassia®, an alpha‐1 antitrypsin augmentation therapy approved by the U.S.